Business Context and Reporting Period
This Form 8-K reports on the results of the 2020 Annual Meeting of Stockholders held by MEDICINOVA, INC. on June 16, 2020. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol MNOV.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's Form 10-K or 10-Q for financial statements.
Material Changes and Voting Results
On the record date of April 22, 2020, the company had 44,067,859 shares of common stock issued and outstanding. A quorum was established with 33,495,522 shares present. Three proposals were submitted and approved:
- Election of Directors: Two Class I Director nominees were elected to serve until the 2023 Annual Meeting.
- Ratification of Auditors: The selection of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020, was ratified.
- Equity Plan Amendment: An amendment to the 2013 Equity Incentive Plan to increase the number of issuable shares by 1,500,000 was approved.
Voting Breakdown
| Proposal | For | Against | Abstain |
|---|---|---|---|
| Election of Dr. Jeff Himawan | 25,755,439 | 4,770,208 | 1,266,923 |
| Election of Hideki Nagao | 27,733,449 | 2,789,816 | 1,269,305 |
| Ratify BDO USA, LLP | 30,060,394 | 2,109,514 | 1,324,414 |
| Amend 2013 Equity Incentive Plan | 26,342,973 | 4,196,284 | 1,256,513 |
Guidance, Outlook, and Risks
This filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. It strictly reports the administrative outcomes of the shareholder meeting.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (44,067,859) against the most recent quarterly filing to confirm capitalization changes.
- Review the definitive proxy statement filed on April 27, 2020, for detailed biographies of the elected directors and the specific terms of the equity plan amendment.
- Confirm the impact of the 1,500,000 share increase on the 2013 Equity Incentive Plan regarding potential future dilution.
- Note that the filing does not contain financial results; check Form 10-Q for the quarter ended March 31, 2020, for the latest financial data.